Home >> People >> Faculty
QIN Jun

Ph.D.

Professor, Principal Investigator

Laboratory of Epigenetic Regulation in Tumor Plasticity

Email: qinjun@sinh.ac.cn

Tel: 86-21-54923326

Brief Biography:

2017 - Present Professor, Principal Investigator, Shanghai Institute of Nutrition and Health, CAS

2014 - 2016 Professor, Principal Investigator, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, CAS and Shanghai Jiao Tong University School of Medicine

2012-2014 Assistant Professor, Baylor College of Medicine

2005-2012 Postdoctoral Fellow, Baylor College of Medicine

2000-2005 Ph.D., Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences

 

Research Areas:

Plasticity regulation plays a crucial role in drug resistance and tumor metastasis, and it is also one of the main causes of tumor heterogeneity. Plasticity regulation can be understood as the process by which cells change their identity, including differentiation of cells within the same lineage or transdifferentiation or dedifferentiation of cell lineages (for example, targeted therapies for lung cancer and prostate cancer lead to a transition from an adenocarcinoma phenotype to neuroendocrine tumors, as well as the malignant transformation of stem cells, dynamic changes in tumor epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) during tumor metastasis, etc.). Furthermore, plasticity regulation can also extend to changes in the overall phenotype of tumors, such as the progression and evolution of dormant tumors and the phenomena of tumor dormancy and awakening during the metastatic process.

Our research focuses on the core of epigenetic regulation and its influence on tumor cell fate determination and microenvironment remodeling, addressing the significant clinical needs in the diagnosis and treatment of prostate cancer and colorectal cancer. We explore the role of epigenetic regulation in tumor metastasis and drug resistance and propose potential therapeutic strategies based on these findings. We aim to elucidate how epigenetically relevant genes respond to drug treatment, metabolism, inflammation, and other signals to regulate histone modifications and chromatin remodeling, thereby determining the fate and function of tumor and microenvironmental cells.

 

Selected Publications: (*Corresponding Author)

  1. Wang H#, Zhang S#, Pan Q#, Guo J, Li N, Chen L, Xu J, Zhou J, Gu Y, Wang X, Zhang G, Lian Y, Zhang W, Lin N, Jin Z, Zang Y, Lan W, Cheng X, Tan M, Chen F, Jiang J, Liu Q*, Zheng M*, Qin J*. Targeting ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation. Nature Cancer in press
  2. Dong B#, Xu J# *, Huang Y#, Guo J#, Dong Q#, Wang Y#, Li N, Liu Q, Zhang M, Pan Q, Wang H, Jiang J, Chen B, Shen D, Ma Y, Zhai L, Zhang J, Li J*, Xue W*, Tan M*, Qin J*. Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers. Nature Cancer 2024;5(9):1427-1447
  3. Long X#, Zhang S#, Wang Y#, Chen J#, Lu Y#, Hou H#, Lin B#, Li Q, Shen C, Yang R, Zhu H, Cui R, Cao D, Chen G, Wang D, Chen Y, Zhai S, Zeng Z, Wu S, Lou M, Chen J, Zou J, Zheng M*, Qin J*, Wang X*. Targeting JMJD1C to selectively disrupt tumor Treg fitness enhances anti-tumor immunity. Nature Immunology 2024;25,525–536
  4. Wang H#, Li N#, #, Liu Q#, Guo J, Pan Q, Cheng B, Xu J, Dong B, Yang G, Bin Yang B, Xuege Wang X, Gu Y, Zhang G, Lian Y, Zhang W, Zhang M, Li T, Zang Y, Tan M, Li Q, Wang W, Yu Z, Jiang J*, Huang H*, Qin J*. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell 2023;41,1345–1362
  5. Chen M#, Wang K#, Han Y#, Yan S#, Yuan H, Liu Q, Li L, Li N, Zhu H, Lu D, Wang K, Fen Liu F, Luo D, Zhang Y, Jiang J, Li D, Zhang L, Ji H, Hu Zhou, Chen Y*, Qin J*, Gao D*. Identification of XAF1 as an endogenous AKT inhibitor. Cell Rep 2023;42(7):112690
  6. Peng S#, Wang Z#, Tang P#, Wang S#, Huang Y, Xie Q, Wang Y, Tan X, Tang T, Yan X, Xu J, Lan W, Wang L, Zhang D, Wang B, Pan T, Qin J*, Jiang J*, Liu Q*. PHF8-GLUL axis in lipid deposition and tumor growth of clear cell renal cell carcinoma. Sci Adv 2023;9(31):eadf3566
  7. Li N#, Liu Q#, Han Y#, Pei S#, Cheng B, Xu J, Miao X, Pan Q, Wang H, Guo J, Wang X, Zhang G, Lian Y, Zhang W, Zang Y, Tan M, Li Q, Wang X, Xiao Y, Hu G, Jiang J*, Huang H*, Qin J*. ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. Nat Commun 2022;13(1):7281
  8. Ren J#, Li N#, Pei S#, Lian Y, Li L, Peng Y, Liu Q, Guo J, Wang X, Han Y, Zhang G, Wang H, Li Y, Jiang J, Li Q, Tan M, Peng J, Hu G, Xiao Y, Li X*, Lin M*, Qin J*. Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ-stimulated antitumor immunity. J Clin Invest 2022;132(8):e153167
  9. Jia P#, Li X#, Wang X#, Yao L, Xu Y, Hu Y, Xu W, He Z, Zhao Q, Deng Y, Zang Y, Meiyu Zhang M, Zhang Y*, Qin J*, Lu W*. ZMYND8 mediated liquid condensates spatiotemporally decommission the latent super-enhancers during macrophage polarization. Nat Commun 2021;12,6535
  10. Pan Q#, Zhong S#, Wang H#, Wang X, Li N, Li Y, Zhang G, Yuan H, Lian Y, Chen Q, Han Y, Guo J, Liu Q, Qiu T, Jiang J, Li Q, Tan M, Yin H, Peng J*, Xiao Y*, Qin J*. The ZMYND8-regulated Mevalonate Pathway Endows YAP-High Intestinal Cancer with Metabolic Vulnerability. Molecular Cell 2021;81(13):2736-2751
  11. Liu Q#, Pang J#, Wang LA#, Huang Z, Xu J, Yang X, Xie Q, Huang Y, Tang T, Tong D, Liu G, Wang L, Zhang D, Ma Q, Xiao H, Lan W, Qin J*, Jiang J*. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2. J Pathol 2021;253(1):106-118
  12. Qi X, Qiu J, Chang J, Ji Y, Yang Q, Cui G, Sun L, Chai Q, Qin J*, Qiu J*. Brg1 Restrains the Pro-Inflammatory Properties of ILC3s and Modulates Intestinal Immunity. Mucosal Immunol 2021;14(1):38-52
  13. Yuan H#, Han Y#, Wang X#, Li N, Liu Q, Yin Y, Wang H, Pan L, Li L, Song K, Qiu T, Pan Q, Chen Q, Zhang G, Zang Y, Tan M, Zhang J, Li Q, Wang X*, Jiang J*, Qin J*. SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways. Cancer Cell 2020 14;38(3):350-365
  14. Yu T#, Gan S#, Zhu Q#, Dai D, Hou D, Wang Y, Pan Q, Xu J, Zhang X, Liu J, Pei S, Luo X, Peng C, Wu P, Romano S, Mao C, Huang M, Zhu X, Qin J*, Xiao Y*. Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24. Nat Commun 2019;10(1):4353
  15. Ding Y#, Li N #, Dong B#, Guo W, Wei H, Chen Q, Yuan H, Han Y, Chang H, Kan S, Wang X, Pan Q, Wu P, Peng C, Qiu T, Li Q, Gao D*, Xue W*, Qin J*. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. J Clin Invest 2019;129(2):759-773
  16. Chen J, Li N, Yin Y, Zheng N, Min M, Lin B, Zhang L, Long X, Zhang Y, Cai Z, Zhai S, Qin J*, Wang X*. Methyltransferase Nsd2 Ensures Germinal Center Selection by Promoting Adhesive Interactions between B Cells and Follicular Dendritic Cells. Cell Rep 2018 18;25(12):3393-3404
  17. Zhang X, Wang Y, Yuan J, Li N, Pei S, Xu J, Luo X, Mao C, Liu J, Yu T, Gan S, Zheng Q, Liang Y, Guo W, Qiu J, Constantin G, Jin J, Qin J*, Xiao Y*. Macrophage/microglial Ezh2 facilitates autoimmune inflammation through inhibition of Socs3. J Exp Med 2018;215(5):1365-1382
  18. Yuan H#, Li N#, Fu D#, Ren J, Hui J, Peng J, Liu Y, Qiu T, Jiang M, Pan Q, Han Y, Wang X, Li Q, Qin J*. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis. J Clin Invest 2017;127(9):3375-3391
  19. Li Y#, Peng J#, Sun T#, Li N, Zhang L, Ren J, Yuan H, Kan S, Pan Q, Li X, Ding Y, Jiang M, Cong X, Tan M, Ma Y, Fu D, Cai S, Xiaog Y, Wang X, Qin J*. Epithelial EZH2 serves as an epigenetic determinant in experimental colitis by inhibiting TNF-mediated inflammation and apoptosis. Proc Natl Acad Sci U S A 2017;114(19):E3796-E3805
  20. Li N#, Xue W#, Yuan H#, Dong B, Ding Y, Liu Y, Jiang M, Kan S, Sun T, Ren J, Pan Q, Li X, Zhang P, Hu G, Wang Y, Wang X, Li Q, Qin J*. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis. J Clin Invest 2017;127(4):1284-1302
  21. Qin J*#, Lee HJ#, Wu SP, Lin SC, Lanz Rb, Creighton CJ, DeMayo FJ, Tsai SY*, Tsai MJ*. Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer. J Clin Invest 2014;124(11):5013-26
  22. Qin J, Wu SP, Creighton CJ, Dai F, Xie X, Cheng CM, Frolov A, Ayala G, Lin X, Feng XH, Ittmann M, Tsai SJ, Tsai MJ*, Tsai SY*. COUP-TFII inhibits TGF-b-induced growth barrier to promote prostate Tumorigenesis. Nature 2013;493(7431):236-240